Breaking News Instant updates and real-time market news.

AAPL

Apple

, AMZN

Amazon.com

$1,168.36

-6.4 (-0.54%)

12:03
12/26/17
12/26
12:03
12/26/17
12:03

On The Fly: Top stock stories at midday

Stocks opened in negative territory under the weight of Apple (AAPL), which was lower following a report out of Asia that the company was cutting orders to its suppliers. The impact of the worries on Apple's suppliers is leaving the Nasdaq as the day's laggard, while the Dow and S&P have been faring better in comparison. As of yet, though, they have not managed to gain any upside momentum and have spent most of the morning straddling the flat line. ECONOMIC EVENTS: In the U.S., the Dallas Fed manufacturing index bounced 10.3 points to 29.7 in December, topping the consensus forecast for a reading of 20. The Richmond Fed manufacturing index came in at 20, down from its prior reading of 30 and below the 21 consensus estimate. COMPANY NEWS: Shares of Apple (AAPL) are down almost 3% after a Taiwanese newspaper reportedly said the tech giant is telling suppliers that it is trimming its first quarter production expectations. Some notable Apple suppliers that are down following Bloomberg's report citing Taiwan's Economic Daily News include Universal Display (OLED), Lumentum (LITE), Micron (MU), Qorvo (QRVO), Skyworks (SWKS) and Finisar (FNSR)... Amazon (AMZN) announced that Prime membership grew this holiday season, noting that "in one week alone, more than four million people started Prime free trials or began paid memberships to benefit from free two-day, one-day or same-day shipping." The company, which is always stingy with financial specifics, also noted that "tens of millions" of Alexa-enabled devices were sold worldwide during the holiday period. MAJOR MOVERS: Among the notable gainers was Sucampo Pharmaceutical (SCMP), which is up 6% after Mallinckrodt (MNK) announced a deal to acquire the company for $18 per share in a transaction valued at approximately $1.2B. Also higher was Insys Therapeutics (INSY), which rose nearly 19% after the company was granted FDA Fast Track designation for its cannabidiol oral solution for the treatment of Prader-Willi syndrome. Among the noteworthy losers was Portola Pharmaceuticals (PTLA), which dropped 10% after the company announced that the FDA will extend its review of the biologics license application for AndexXa by 90 days. INDEXES: Near midday, the Dow was down 15.90, or 0.06%, to 24,738.16, the Nasdaq was down 28.59, or 0.41%, to 6,931.37, and the S&P 500 was down 2.76, or 0.1%, to 2,680.58.

AAPL

Apple

AMZN

Amazon.com

$1,168.36

-6.4 (-0.54%)

MNK

Mallinckrodt

$23.91

0.59 (2.53%)

SCMP

Sucampo

$17.00

0.05 (0.29%)

OLED

Universal Display

$175.55

-1.35 (-0.76%)

LITE

Lumentum

$52.80

-0.55 (-1.03%)

MU

Micron

$44.12

-0.3 (-0.68%)

QRVO

Qorvo

$67.69

0.21 (0.31%)

SWKS

Skyworks

$97.07

-0.42 (-0.43%)

FNSR

Finisar

$21.39

-0.37 (-1.70%)

INSY

Insys Therapeutics

$7.12

0.09 (1.28%)

  • 08

    Jan

  • 09

    Jan

  • 09

    Jan

  • 09

    Jan

  • 28

    Jan

  • 27

    Feb

  • 18

    Mar

AAPL Apple

12/26/17
LSCM
12/26/17
NO CHANGE
LSCM
Buy
Lake Street says Knowles more likely than Himax to be impacted by Apple weakness
Lake Street analyst Jaeson Schmidt thinks Knowles (KN) is more likely to be impacted by concerns over iPhone X shipment weakness than Himax (HIMX), which is not immune but has the advantage of Android OEMs helping to backfill revenue that may be lost with Apple (AAPL). Amid the reports of concerns over weakness in first quarter iPhone X sales, he has Buy rating on the shares of both of the aforementioned Apple suppliers.
12/26/17
RSBL
12/26/17
NO CHANGE
RSBL
Rosenblatt sees no evidence of more Apple iPhone production cuts
Taiwanese media reports may be confusing the market and could be referring to previously mentioned iPhone 8/8 Plus production cuts, said Rosenblatt analysts, who added that they find no evidence in their research of further order cuts after the holiday season.
12/21/17
MSCO
12/21/17
NO CHANGE
Target $200
MSCO
Overweight
iPhone X helping Apple accelerate share gains in China, says Morgan Stanley
Morgan Stanley analyst Katy Huberty said new data through the first 16 days of iPhone X availability in China show that adoption of the high-end device is on a faster pace than the iPhone 8 or 8 Plus, which she sees fueling an acceleration of Apple smartphone share gains. The analyst, who also noted that Google Trends data corroborate iPhone strength in China, said Apple remains her top pick entering 2018 and she keeps an Overweight rating on the stock with a $200 price target.
12/26/17
RILY
12/26/17
NO CHANGE
RILY
Apple estimates at limited risk after cautious iPhone report, says B. Riley FBR
B. Riley FBR analyst Craig Ellis noted the recent "divergent" reports on iPhone X demand from two Asian sources, namely Digitimes and Taiwan's Economic Daily News, pointing out that Digitimes seemed to imply a positive take about iPhone X forecasts while EDN discussed a post-holiday order cut made by the company to iPhone suppliers. Ellis said he would be opportunistic in adding to positions in some of the Apple supplier stocks being impacted by the EDN report, as he believes fundamentals continue to track toward consensus expectations, with upside possible. Ellis lists Broadcom (AVGO), Skyworks (SWKS), Applied Materials (AMAT) and Lam Research (LRCX) as among the Apple suppliers and semi equipment suppliers on which the firm maintains Buy ratings.
AMZN Amazon.com
$1,168.36

-6.4 (-0.54%)

12/19/17
KEYB
12/19/17
UPGRADE
Target $21
KEYB
Overweight
Brandywine Realty upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Jordan Sadler upgraded Brandywine Realty (BDN) to Overweight from Sector Weight with a price target of $21. Sadler cites the company's execution in leasing, development discipline, and completion of its disposition program that positions the portfolio for same-store NOI growth that the management forecasts at 2%-5% through 2021. The analyst also notes a potential catalyst in Amazon (AMZN) choosing a location for its HQ2 - if Philadelphia, Austin, or North Virgina are selected, the company could benefit.
12/26/17
SBSH
12/26/17
NO CHANGE
Target $110
SBSH
Buy
Citi ups XPO target to $110, sees takeover value closer to $120
Citi analyst Christian Wetherbee raised his price target for XPO Logistics (XPO) to $110 from $75 after Recode reported Friday that Home Depot (HD) has contemplated an acquisition of the company, partially as a defensive move to prevent Amazon (AMZN) from doing the same. In a research note titled "Buyer or Seller, There are Lots of Ways to Win," Wetherbee argues that XPO CEO Brad Jacobs is likely to be willing to maximize shareholder value either as a buyer or seller if the opportunity was right. Friday's article likely adds a takeout premium to XPO shares, at least near-term, the analyst adds. His new price target reflects this dynamic along with a "strong fundamental story." The analyst, however, believes a takeout bid would need to be higher, closer to $120 per share, due to the "significant potential value" XPO can create as a standalone company. Wetherbee keeps a Buy rating on XPO shares, which closed Friday up 14%, or $11.32, to $90.01.
12/22/17
DBAB
12/22/17
NO CHANGE
DBAB
Strategic rationale for Home Depot buying XPO 'very clear,' says Deutsche Bank
Deutsche Bank analyst Amit Mehrotra noted that Recode reported that Home Depot (HD) has held internal talks about a potential acquisition bid for XPO Logistics (XPO), which is also said to be possibly being considered by Amazon (AMZN) as a takeover target. The news highlights the strategic and scarcity value of XPO's assets, said Mehrotra, who believes the company has "by far" the biggest heavy goods last mile business in the country. From a valuation standpoint, the analyst said his $110 price target is conservative and does not include any assumption of corporate tax reform, which would drive his target to $130. He maintains a Buy rating on XPO, whose stock is up 14% to $90 per share heading into the close.
12/21/17
RBCM
12/21/17
NO CHANGE
Target $1200
RBCM
Outperform
Amazon revenue from Alexa could grow to $10-$11B by 2020, says RBC Capital
RBC Capital analyst Mark Mahaney said the firm's latest annual Alexa survey has left him more convinced of the potential long-term impact the voice-powered devices can have on Amazon. He expects Alexa's value proposition to increase in power as awareness and ownership rise and believes Amazon could see $10B-$11B in Alexa-related revenue by 2020. Mahaney maintains an Outperform rating and $1,200 price target on Amazon shares.
MNK Mallinckrodt
$23.91

0.59 (2.53%)

12/22/17
WELS
12/22/17
NO CHANGE
WELS
Market Perform
Wells says tax act net effect seems positive for Mallinckrodt non-GAAP EPS
After Mallinckrodt released a regulatory filing this morning stating the company's anticipated puts and takes related to the passage of the U.S. Tax Cut and Jobs Act, Wells Fargo analyst David Maris said he believes the net effect of the TCJA seems positive for the company's non-GAAP EPS. Maris keeps a Market Perform rating on Mallinckrodt shares.
11/22/17
11/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Salesforce (CRM) downgraded to Neutral from Buy at Roth Capital with analyst Richard Baldry citing the 59% year-to-date rally in the shares. 2. Bloomin' Brands (BLMN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gregory Francfort citing news of Jana Partners' 8.7% stake and subsequent share price spike. 3. Halozyme (HALO) assumed with an Equal Weight from Overweight at Barclays with analyst Gena Wang saying she believes the potential of Halozyme's Enhanze technology is largely reflected in the stock following the recent rally. 4. Mallinckrodt (MNK) downgraded to Perform from Outperform at Oppenheimer with analyst Derek Archila saying he's been "flat out wrong" on the shares. 5. Cytokinetics (CYTK) was downgraded to Neutral from Overweight at Cantor Fitzgerald and to Buy from Strong Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/17
LEHM
12/12/17
NO CHANGE
Target $23
LEHM
Equal Weight
Mallinckrodt management keeps conviction in Acthar, says Barclays
Barclays analyst Douglas Tsao says Mallinckrodt management in meetings last week reiterated their conviction in the Acthar franchise's durability. The analyst continues to believe the franchise should prove "reasonably durable," but after Q3's miss, he does not expect a "v-shaped" recovery next year. Further, Acthar,'s pressure could worsen if additional payers implement policies that affected Q3, Tsao tells investors in a research note titled "It always comes back to Acthar." The analyst keeps an Equal Weight rating on Mallinckrodt with a $23 price target.
11/22/17
OPCO
11/22/17
DOWNGRADE
OPCO
Perform
Mallinckrodt downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Derek Archila downgraded Mallinckrodt to Perform saying he's been "flat out wrong" on the shares. The thesis of branded growth and material margin expansion has not and is unlikely to play out within the next 12-18 months, Archila tells investors in a research note. He sees "little-to-no visibility" on Acthar growth outside of management's remarks on the payer pushback/patient abandonment issues. Further, Archila is not certain whether the company can remedy the Acthar growth issue in a timely manner. He pulled his price target for Mallinckrodt shares.
SCMP Sucampo
$17.00

0.05 (0.29%)

12/07/17
MAXM
12/07/17
NO CHANGE
Target $23
MAXM
Buy
Sucampo shares undervalued based on fundamentals, says Maxim
Following a Bloomberg report that said Sucampo may be entertaining suitors, Maxim analyst Jason Kolbert said this would be plausible given that the company's shares are undervalued, it is generating free cash flow and has a strong pipeline. However, he has no specific knowledge to confirm the report, Kolbert adds. He has a Buy rating and $23 price target on Sucampo shares.
12/26/17
MAXM
12/26/17
DOWNGRADE
MAXM
Hold
Sucampo downgraded to Hold from Buy at Maxim
Sucampo (SCMP) is being acquired by Mallinckrodt (MNK) for $18/share.
12/19/17
12/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Michael Kors (KORS) was initiated with a Buy at Needham while Tapestry (TPR) was initiated with a Hold. 2. Sherwin-Williams (SHW) initiated with a Strong Buy, named a Top Pick at Raymond James. 3. Sucampo (SCMP) initiated with a Buy at Nomura Instinet. 4. Semtech (SMTC) initiated with a Neutral at Piper Jaffray. 5. Mimecast (MIME) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/17
NOMU
12/18/17
INITIATION
Target $43
NOMU
Buy
Sucampo initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Christopher Marai started Sucampo with a Buy rating and $43 price target, stating that he believes its current valuation primarily reflects cash flows from its currently marketed drug, Amitiza, and neglects potentially newer pipeline products that could double revenues to $500M by 2020.
OLED Universal Display
$175.55

-1.35 (-0.76%)

12/08/17
DBAB
12/08/17
NO CHANGE
Target $190
DBAB
Buy
Universal Display price target raised to $190 from $170 at Deutsche Bank
Deutsche Bank analyst Sidney Ho raised his price target for Universal Display to $190 after the company announced that is has signed a multi-year portfolio license and supply agreement with BOE Technology Group. The analyst believes the news bodes well for the company's Samsung negotiation. Ho keeps a Buy rating on Universal Display.
11/30/17
EVER
11/30/17
INITIATION
Target $225
EVER
Outperform
Universal Display initiated with an Outperform at Evercore ISI
Evercore ISI analyst C.J. Muse initiated Universal Display with an Outperform and $225 price target saying it is a pure-play in the fast growing OLED market. Muse sees a "significant opportunity" for the company as OLED smartphone penetration continues to growth, OLED TVs go mainstream on new disposition processes, and blue phosphorescent emitters are introduced. The analyst concludes by saying Universal Display's patent portfolio will allow the company to continue to dominate the market through material sales and a royalty/licensing model.
11/10/17
COWN
11/10/17
NO CHANGE
Target $195
COWN
Outperform
Universal Display price target raised to $195 from $155 at Cowen
Cowen analyst Robert Stone raised his price target on Universal Display (OLED) to $195 from $155 as he believes the company is poised for a strong 2018. The analyst cited several triggers, including its multi-year deal with Samsung (SSNLF) and the continued ramp of Apple's (AAPL) iPhone X. Stone reiterated his Outperform rating on Universal Display shares.
11/03/17
GABE
11/03/17
DOWNGRADE
GABE
Hold
Universal Display downgraded to Hold from Buy at Gabelli
Gabelli analyst Hendi Susanto downgraded Universal Display to Hold based on valuation and maintained a PMV of $125.
LITE Lumentum
$52.80

-0.55 (-1.03%)

12/13/17
RSBL
12/13/17
NO CHANGE
RSBL
Lumentum weakness a buying opportunity, says Rosenblatt
12/20/17
RILY
12/20/17
NO CHANGE
Target $89
RILY
Buy
Lumentum to supply China Telecom's ROADM deployment, says B. Riley FBR
B. Riley FBR analyst Dave Kang says multiple Chinese media sources indicate that China Telecom (CHA) plans to deploy a ROADM-based network in both Northern and Southern China after successfully deploying a similar network in the middle and lower sections of the Yangtze River region. The analyst believes Lumentum (LITE) will be the primary supplier of ROADMs, or reconfigurable optical add/drop multiplexers. He points out the company's management recently indicated that several products, including ROADMs, have been expedited by Chinese customers. Further, Kang expects China Mobile (CHL) to follow China Telecom's lead, most likely in mid-2018. The analyst thinks the Chinese ROADM cycle will be an important catalyst for Lumentum in 2018 and beyond. The stock is up 11c to $53.51 in afternoon trading. Kang has a Buy rating on Lumentum with an $89 price target.
12/18/17
NEED
12/18/17
NO CHANGE
Target $80
NEED
Strong Buy
Lumentum is top 2019 idea in Optical and Networking, says Needham
Needham analyst Alex Henderson keeps his Strong Buy rating on Lumentum with a price target of $80. Henderson says the company's dominant market shares in its core ROADM and Pump Laser businesses distinguish it from competition in the optical space challenged with growth and pricing factors. The analyst says the company is his "Single Best Idea" in the Optical and Networking sector thanks to its mix of Optical fundamentals and "exceptional opportunity" in 3D.
12/13/17
RSBL
12/13/17
NO CHANGE
RSBL
Apple's investment in Finisar's new fab a neutral for Lumentum, says Rosenblatt
Rosenblatt analyst Jun Zhang said Apple's (AAPL) investment in Finisar's (FNSR) new fab is a neutral for Lumentum (LITE). Zhang said Finisar might not be able to supply the Android market as it sold all its potential capacity to Apple, reducing competition for Lumentum in that market. Further, the fab will take several quarters to prepare while the competitive landscape is not likely to change in 2018-2019, leaving Lumentum as the primary supplier to Apple, the analyst wrote.
MU Micron
$44.12

-0.3 (-0.68%)

12/20/17
RSBL
12/20/17
NO CHANGE
Target $85
RSBL
Buy
Micron price target raised to $85 from $75 at Rosenblatt
12/20/17
FBCO
12/20/17
NO CHANGE
Target $60
FBCO
Outperform
Micron price target raised to $60 from $50 at Credit Suisse
Credit Suisse analyst John Pitzer raised his price target for Micron to $60 from $50 after the company reported Q1 results and guided Q2 well above consensus. The analyst reiterates an Outperform rating on the shares.
12/20/17
NEED
12/20/17
NO CHANGE
Target $76
NEED
Buy
Micron multiple should rise as investors appreciate secular shift, says Needham
Needham analyst Rajvindra Gill noted that Micron is trading well below its historical average P/E multiple of 8-10x, but thinks its multiple should rise as investors come to understand how the company benefits from the secular transition away from PCs and smartphones to high-performance computing applications, which brings with it higher capacity and favorable pricing. Gill maintains a Buy rating and $76 price target on Micron following the company's "record" quarter and guidance.
12/20/17
RSBL
12/20/17
NO CHANGE
Target $85
RSBL
Buy
Rosenblatt ups Micron price target to Street-high $85
Rosenblatt analyst Hans Mosesmann raised his price target for Micron Technology to $85 from $75 and reiterates a Buy rating on the shares following last night's better than expected results and guidance. The analyst believes "impressive demand and content dynamics" will continue to drive the memory cycle.
QRVO Qorvo
$67.69

0.21 (0.31%)

11/15/17
JPMS
11/15/17
NO CHANGE
Target $88
JPMS
Overweight
Qorvo shares remain undervalued, says JPMorgan
JPMorgan analyst Bill Peterson says that despite rallying 50% year-to-date, shares of Qorvo remain undervalued. The company's non-mobile, or Infrastructure and Defense Products, business continues to be underappreciated by investors, Peterson tells investors in a research note. He expects continued margin expansion and solid free cash flow generation and reiterates an Overweight rating on Qorvo with an $88 price target.
11/14/17
OTRG
11/14/17
NO CHANGE
OTRG
Qorvo may be running Galaxy Note8's high-band power amplifier, says OTR Global
12/11/17
SBSH
12/11/17
NO CHANGE
SBSH
Citi 'getting more nervous' on semiconductors after Asia trip
Following a trip last week to Asia meeting with companies across the technology supply chain, Citi analyst Christopher Danely says he's "getting more nervous" on the semiconductor sector. While demand from the PC end market remains strong, the NAND market remains weak and data points on Apple's (AAPL) iPhone were mixed, Danely tells investors in a research note. The analyst saw signs of an inventory build and believes upside to consensus estimates is declining. He feels momentum is slowing in the semiconductor space. Danely's top pick is Microchip (MCHP) and he's also Buy-rated on Texas Instruments (TXN), Applied Materials (AMAT), Nvidia (NVDA), Skyworks (SWKS), ON Semiconductor (ON) and Micron (MU). The analyst's checks indicate slower than expected iPhone X and 8 demand but stronger iPhone 7 demand. He views this as bad for Skyworks and Qorvo (QRVO) and good for Analog Devices (ADI).
12/15/17
JPMS
12/15/17
NO CHANGE
JPMS
JPMorgan sees opportunities in Wireless Semiconductors, prefers Qorvo
JPMorgan analyst Bill Peterson believes the recent pullback in Wireless Semiconductor names, specifically Apple-exposed stocks, creates a good opportunity for investors to take long positions. The analyst sees the most upside in Qorvo (QRVO). He believes fears of production cuts and demand weakness are overblown. The December quarter and outlook for the March quarter are tracking to company expectations that have been built on conservative prospects for smartphone demand, Peterson tells investors in a research note.
SWKS Skyworks
$97.07

-0.42 (-0.43%)

12/20/17
PIPR
12/20/17
INITIATION
Target $115
PIPR
Overweight
Skyworks initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Harsh Kumar started Skyworks Solutions with an Overweight rating and $115 price target. The analyst believes the company will continue to perform well in the mobile market over the near and medium term. Skyworks is well positioned to gain share and content in marquee handsets in both the U.S. and China, Kumar tells investors in a research note.
FNSR Finisar
$21.39

-0.37 (-1.70%)

12/14/17
CHLM
12/14/17
NO CHANGE
Target $28
CHLM
Buy
Finisar price target raised to $28 after Apple award at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for Finisar (FNSR) to $28 from $24 following Apple's (AAPL) award of $390M for VCSEL capacity/RD, which he believes is a "strong confirmation" of the market opportunity for 3D sensing, and a sign that the market is likely to be undersupplied for a number of quarters. The analyst reiterates a Buy rating on Finisar shares.
12/13/17
STFL
12/13/17
NO CHANGE
Target $26
STFL
Buy
Finisar price target raised to $26 after Apple award at Stifel
Stifel analyst Patrick Newton raised his price target for Finisar (FNSR) to $26 from $22 after the company announced it will receive $390M from Apple's (AAPL) Advanced Manufacturing Fund for building out its VCSEL production capabilities at its recently purchased Sherman facility. The analyst sees this as a win, and notes it further legitimizes 3D Sensing technology, eliminating any investor concern that Apple may revert to finger print sensors in the future as some data on iPhone X sell through has lagged expectations. He reiterates a Buy rating on Finisar's shares.
12/13/17
PIPR
12/13/17
NO CHANGE
Target $28
PIPR
Overweight
Finisar price target raised to $28 after Apple award at Piper Jaffray
Piper Jaffray analyst Troy Jensen raised his price target on Finisar (FNSR) to $28 from $22 after the company was awarded a $390M investment from Apple (AAPL) to scale VCSEL capacity, saying that he believes the deal solidifies a long-term relationship between the companies. Jensen has previously assumed Finisar only had 25% of the high-powered VCSEL for the iPhone X and Lumentum (LITE) had 75% of the high-power and 100% of the low-power VCSEL, but he now believes Finisar could capture significantly more share than previously expected, he tells investors.
INSY Insys Therapeutics
$7.12

0.09 (1.28%)

03/24/17
JANY
03/24/17
NO CHANGE
Target $19
JANY
Buy
Janney says Insys receipt of DEA decision removes 'stonewalling' fear
Janney Capital analyst Ken Trbovich said Insys Therapeutics' receipt of DEA scheduling of Syndros sets up a launch in the second half of the year, giving its sales reps a second product to promote and the company an opportunity to return to growth. Furthermore, the decision removes uncertainty about whether the company's ongoing DOJ investigation led to "stonewalling" of the company's regulatory efforts, noting that "while slow," both the DEA and FDA eventually took action. He keeps a Buy rating and $19 fair value estimate on Insys shares.
07/21/17
JANY
07/21/17
NO CHANGE
Target $16
JANY
Buy
Subsys ANDA somewhat negative for Insys, but not unexpected, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA's Paragraph IV certifications list earlier this week showed that Insys had received an ANDA filing for Subsys on May 22, which he views as "somewhat negative," but also "not unexpected." While the ANDA raises the possibility of a generic sooner rather than later, Trbovich sees no risk for a generic Subsys until 2020 at the earliest and thinks the company's patents could prevent generic entry until as late as 2030. He keeps a Buy rating and $16 fair value estimate on Insys shares.
04/06/17
OPCO
04/06/17
NO CHANGE
OPCO
Perform
DoJ settlement not 'end all, be all' for Insys Therapeutics, says Oppenheimer
Oppenheimer analyst Derek Archila thinks Insys Therapeutics' shares are likely to react favorably on an announcement of a DoJ settlement, but he does not view it as the "end all, be all" clearing event for the company as he continues to worry about deteriorating Subsys sales and consensus forecasts for Syndros that look too high. The analyst reiterates a Perform rating on the shares.
05/10/17
PIPR
05/10/17
DOWNGRADE
Target $10
PIPR
Neutral
Insys Therapeutics downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Insys Therapeutics to Neutral following the Q1 results and halved his price target for the shares to $10 from $20. Prescription trends for Subsys have been consistently weak and will remain so given the scrutiny of the opioid space and Insys in particular, Amsellem tells investors in a post-earnings research note.

TODAY'S FREE FLY STORIES

03:05
01/22/18
01/22
03:05
01/22/18
03:05
General news
FX Update: The dollar dipped at the open of Asia-Pacific dealings »

FX Update: The dollar…

02:55
01/22/18
01/22
02:55
01/22/18
02:55
Conference/Events
Morgan Stanley transportation analysts hold an analyst/industry conference call »

ASEAN Transportation VP…

FCX

Freeport McMoRan

$19.96

0.56 (2.89%)

21:10
01/21/18
01/21
21:10
01/21/18
21:10
Downgrade
Freeport McMoRan rating change at CIBC »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

DCM

NTT DoCoMo

$24.74

0.08 (0.32%)

21:09
01/21/18
01/21
21:09
01/21/18
21:09
Downgrade
NTT DoCoMo rating change at HSBC »

NTT DoCoMo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$53.01

0.65 (1.24%)

, PETS

PetMed Express

$53.24

2.67 (5.28%)

20:25
01/21/18
01/21
20:25
01/21/18
20:25
Earnings
Notable companies reporting before Monday's open »

Notable companies…

HAL

Halliburton

$53.01

0.65 (1.24%)

PETS

PetMed Express

$53.24

2.67 (5.28%)

OPB

Opus Bank

$28.70

0.05 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

20:00
01/21/18
01/21
20:00
01/21/18
20:00
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

SNE

Sony

$49.89

0.72 (1.46%)

BA

Boeing

$337.73

-2.43 (-0.71%)

WMT

Walmart

$104.59

0.29 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 07

    Feb

  • 20

    Feb

  • 21

    Feb

  • 28

    Feb

  • 18

    Mar

XRX

Xerox

$31.80

0.43 (1.37%)

19:18
01/21/18
01/21
19:18
01/21/18
19:18
Periodicals
Icahn, Deason pushing for Xerox to explored sale, WSJ reports »

Carl Icahn and Darwin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

18:22
01/21/18
01/21
18:22
01/21/18
18:22
Periodicals
Facebook to open three new digital training hubs in Europe, Reuters says »

Facebook said it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

TWX

Time Warner

$93.36

0.39 (0.42%)

, CMCSA

Comcast

$42.50

0.65 (1.55%)

17:56
01/21/18
01/21
17:56
01/21/18
17:56
Hot Stocks
Box Office Battle: 'Jumanji' wins weekend with $20M »

Once again, Sony's…

TWX

Time Warner

$93.36

0.39 (0.42%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

SNE

Sony

$49.89

0.72 (1.46%)

FOX

21st Century Fox

$36.26

0.53 (1.48%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

LGF.A

Lionsgate

$35.42

0.92 (2.67%)

DIS

Disney

$110.59

0.17 (0.15%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

CTIC

CTI BioPharma

16:11
01/21/18
01/21
16:11
01/21/18
16:11
Conference/Events
CTI BioPharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ZSAN

Zosano Pharma

$0.45

-0.0387 (-7.92%)

16:00
01/21/18
01/21
16:00
01/21/18
16:00
Conference/Events
Zosano Pharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SANM

Sanmina

$35.45

0.5 (1.43%)

15:39
01/21/18
01/21
15:39
01/21/18
15:39
Conference/Events
Sanmina to hold a conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

12:05
01/21/18
01/21
12:05
01/21/18
12:05
Periodicals
Amazon automated grocery store opens Monday, Reuters says »

Amazon will open its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 18

    Mar

TWTR

Twitter

$23.66

-0.38 (-1.58%)

09:07
01/21/18
01/21
09:07
01/21/18
09:07
Periodicals
Twitter COO in discussions to become SoFi CEO, WSJ reports »

Twitter's COO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLF

Cleveland-Cliffs

$8.49

0.08 (0.95%)

09:02
01/21/18
01/21
09:02
01/21/18
09:02
Hot Stocks
Cleveland-Cliffs addresses ''inaccurate media reports' on Nashwauk property »

Cleveland-Cliffs said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.